Acromegaly is a rare hormonal disorder in which the body produces excessive growth hormone (GH), leading to abnormal growth of certain body parts. It stems from a benign tumor that sits on the ...

“If we can own rights again, which we know we can, the next question becomes, ‘what rights do we want to own?'” Grant said. “As it relates to the creation of content, obviously what always has broken ...

The journal Pituitary has highlighted research led by Manel Puig, head of the Endocrine, Thyroid and Obesity Research Group at the Germans Trias i Pujol Research Institute (IGTP), which explores the ...

Palsonify is a medicine for certain people with acromegaly. Acromegaly is a rare disorder that happens when your body makes too much growth hormone (GH). This hormone is made and released in the ...

Drugs for the rare hormone disorder acromegaly include older engineered peptides administered as frequent injections. A new FDA approval brings acromegaly patients the choice of a once-daily pill that ...

Crinetics Pharmaceuticals (NASDAQ:CRNX) has received approval for its lead asset, Palsonify (paltusotine), as a first-line treatment for adults with acromegaly, a rare condition characterized by ...

Paltusotine is the first once-daily oral therapy approved for acromegaly, offering a non-invasive alternative to injections. PATHFNDR-1 and PATHFNDR-2 trials showed significant efficacy in IGF-1 ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved paltusotine for first-line treatment of patients with acromegaly who did not respond to or ...

Credit: Crinetics. Palsonify is supplied as a 20mg and 30mg tablet. Palsonify is an oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist. The Food and Drug Administration (FDA) ...

What Is Palsonify, and Why Does It Matter? Palsonify (paltusotine) is a new once-daily oral medicine approved to treat adults with acromegaly who either didn’t get much help from surgery or cannot ...

Sept 25 (Reuters) - The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' (CRNX.O), opens new tab drug to treat a rare hormonal disorder on Thursday, making it the first once-daily ...

After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a game-changing treatment for the rare growth disorder acromegaly. The FDA on Thursday ...